Study Summary
This trial suggests that GM-CSF may be a better post-transplant treatment than G-CSF, with the potential to lower the risk of infection.
- Transplant-Related Blood Cancer
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 9 Secondary · Reporting Duration: 12 months following initiation of treatment
Trial Safety
Phase-Based Safety
Side Effects for
Awards & Highlights
Trial Design
1 Treatment Group
GM-CSF post-transplant
1 of 1
Experimental Treatment
38 Total Participants · 1 Treatment Group
Primary Treatment: Sargramostim · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 78 · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What situations is Sargramostim most frequently employed to manage?
"Sargramostim is traditionally used to treat serious infections, but it has also been useful in the treatment of lymphoma, Hodgkin's disease, bone marrow transplantation and forms of leukemia." - Anonymous Online Contributor
Are there any significant risks associated with Sargramostim administration?
"Our team has assessed sargramostim's safety to be a 2, as the clinical data is only indicative of its security, not efficacy." - Anonymous Online Contributor
How many participants are included in this trial?
"Affirmative. Information listed on clinicaltrials.gov indicates that this medical investigation, first published on May 18th 2020, is currently recruiting patients. 38 participants are needed from 1 centre across the country." - Anonymous Online Contributor
Is the trial currently taking on new participants?
"Affirmative, the information on clinicaltrials.gov displays that this experiment is actively seeking candidates. This trial was initially published on May 18th 2020 and updated most recently on October 19th 2022. 38 participants are required from 1 centre for enrolment in this study." - Anonymous Online Contributor
Are elderly individuals eligible to participate in this clinical experiment?
"This medical experiment is open to patients with an age range of 18-78 years." - Anonymous Online Contributor
Is it possible to become a participant in this research endeavor?
"In order to qualify for this clinical trial, applicants must have a hematologic neoplasm and be between 18-78 years of age. The research team is hoping to recruit 38 people total." - Anonymous Online Contributor
Are there any precedent research projects involving Sargramostim?
"At the moment, 43 clinical trials are being conducted for Sargramostim. Five of these experiments have entered Phase 3. The lion's share of studies related to this drug take place in Seattle, Washington yet there are 1888 distinct sites conducting research into its efficacy." - Anonymous Online Contributor